A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals
National Institutes of Health · NIH NIAID DEA OA OFC ACQUISITIONS
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation PHS-2025-1 in this department, oldest first.
- Jul 18, 2024Pre-solicitationOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives. THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2025-1 is anticipat… (show all)
ed to be made available on or around August 2, 2024, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of October 18, 2024 for receipt of proposals. The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.* * Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. � 121.702. THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2025-1 NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Topic 025 Development of a versatile small footprint benchtop device to perform batch evaporation Topic 026 Scalable Generation of Liver and Brain Organoids Derived from Human iPS Cells. NATIONAL CANCER INSTITUTE (NCI): Topic 466 Novel Delivery Systems for RNA-based Cancer Vaccines Topic 467 Development of Cancer Immunoprevention Agents Topic 468 Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies Topic 469 Development of Novel Therapeutics for HPV-related Precancer Topic 470 Precision Nutrition Interventions to Reduce Cancer-Related Symptoms Topic 471 Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention Topic 472 Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer Topic 473 Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins in Oropharyngeal Cancer Topic 474 Point of Care Technologies for GI Cancer Prevention and Early Detection Topic 475 Development of Digital Biomarkers and Endpoints for Clinical Cancer Care Topic 476 Digital Twin Software for Optimization of Cancer Radiation Therapy Topic 477 Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment Topic 478 Advanced Biomaterials to Improve Cancer Modeling for Research NATIONAL INSTITUTE ON AGING (NIA): Topic 011 Digital Technologies as Tools to Screen and Monitor Alzheimer�s Disease (AD) and Related Dementias (ADRD) Topic 012 Modeling Aging through Microphysiological Systems Topic 013 Leveraging Multimodal and Generative Artificial Intelligence to Advance the Application of Social Robotics in Caregiving NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM Topic 020 Alcohol-activated locking systems for firearms and firearm storage units? Topic 021 Data science tools for accelerating alcohol research? Topic 022 Non-invasive Wearable Alcohol Sensor NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Topic 137 New Drug Classes with Novel Mechanisms of Action for HIV, Hepatitis B, and Tuberculosis Topic 138 Devices and Materials-Based Platforms for the Delivery of Broadly Neutralizing Antibodies Topic 139 Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection Topic 140 Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune- Mediated Diseases Topic 141 Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models Topic 142 Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases Topic 143 Development of Diagnostics for Mycoplasma genitalium Infection Topic 144 Development of Medical Interventions for Treating Non-Tuberculosis Mycobacterial (NTM) Infections Topic 145 Diagnostics to Detect Host Immunity to Coccidioidomycosis (Valley fever) or Histoplasmosis Topic 146 Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential Topic 147 Software or Web Services to Assess Quality and Reproducibility of Data and Information about Therapeutics and Vaccines NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH): Topic 001 Point-of-Care and Pharmacy-based Antiretroviral Drug Adherence Assays Topic 002 Development of novel In-vitro and In-vivo Models to support NeuroHIV Research CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID): Topic 032 Canine Vaccines to Prevent Tick Bites Topic 033 Rapid, Portable, Point-of-Care Carbapenem Resistant Acinetobacter Colonization Screening Diagnostic Topic 034 Improved Diagnostic Assays for Foodborne and Waterborne Bacterial Pathogens Topic 035 Improved Diagnostic Assays for Parasitic Diseases Topic 036 Developing an Over-the-Counter Diagnostic for Valley Fever Topic 037 Enhancing the CDC Autocidal Gravid Ovitrap to Control Dengue Vectors NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Topic 038 Development of a Molecular Panel to Detect Febrile Rash Illnesses Topic 039 Synthetic IgM Antibody Controls for Measles, Mumps, and Rubella Assays NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL (NCIPC) Topic 001 Data Science Solutions to Characterize Polysubstance Use Behavior from Online Sources NOTE � SBIR / STTR GRANT OPPORTUNITIES SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://seed.nih.gov/small-business-funding/find-funding/sbir-sttr-funding-opportunities#omnibus-solicitations. Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th. To understand better the differences between grants and contracts, see https://seed.nih.gov/apply
Who won similar work
26 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) AN11.
Single-winner award sizes (16): middle half $4.4M to $20.3M, median $17.4M; range $552K to $34.9M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| UNIVERSITY OF MARYLAND, BALTIMORE Baltimore MD 21201 USA | 2 | $30.8M | Aug 6, 2026 |
| The TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 USA | 2 | $17.1M + 1 shared | Sep 25, 2026 |
| MRIGLOBAL Kansas City MO 64110 USA | 2 | $5.0M + 1 shared | Jul 17, 2026 |
| THE MCLEAN HOSPITAL CORPORATION | 1 | $34.9M | Nov 21, 2025 |
| UNIVERSITY OF MIAMI Coral Gables FL 33146 USA | 1 | $26.6M | Nov 21, 2025 |
| WESTAT, INC. | 1 | $21.4M | Sep 25, 2026 |
| RESEARCH TRIANGLE INSTITUTE Durham NC 27709 USA | 1 | $20.0M | Mar 17, 2025 |
| UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Pittsburgh PA 15260 USA | 1 | $19.9M | Nov 21, 2025 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York NY 10029 USA | 1 | $18.5M | Nov 21, 2025 |
| Greater Los Angeles Veterans Research and Education Foundation Los Angeles CA 90073 USA | 1 | $17.7M | Nov 21, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Sep 28, 2026Versiti Blood Health, Inc.$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation StudyShared multiple-award ceiling, not one company's win (Materiality N/A)
- Sep 28, 2026EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR MAILSTOP 1599-001-1BA Atlanta GA 30322 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation StudyShared multiple-award ceiling, not one company's win (Materiality N/A)
- Sep 25, 2026The TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 USA$17.1MA--Recipient Epidemiology and Donor Evaluation StudyNo listed company matched (Materiality N/A)
- Sep 25, 2026The TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation StudyShared multiple-award ceiling, not one company's win (Materiality N/A)
- Sep 25, 2026WESTAT, INC.$21.4MA--REDS-V-Data Coordinating CenterNo listed company matched (Materiality N/A)
- Sep 25, 2026VITALANT 9305 E VIA DE VENTURA Scottsdale AZ 85258 USA$7.4M (shared ceiling)A--The Recipient Epidemiology and Donor Evaluation StShared multiple-award ceiling, not one company's win (Materiality N/A)
- Aug 6, 2026UNIVERSITY OF MARYLAND, BALTIMORE Baltimore MD 21201 USA$552KRNCP PORTFOLIO-WIDE DOSIMETRY VERIFICATION SERVICESNo listed company matched (Materiality N/A)
- Jul 17, 2026MRIGLOBAL Kansas City MO 64110 USA$5.0MAnalytical Services Center for Medications Development ProgramNo listed company matched (Materiality N/A)
- May 5, 2026MRIGLOBAL Kansas City MO 64110 USA$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)Shared multiple-award ceiling, not one company's win (Materiality N/A)
- May 5, 2026CURIA GLOBAL INC$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)Shared multiple-award ceiling, not one company's win (Materiality N/A)
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.